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INTRODUCTION
Significant improvements in medical care and lifestyle in re-
cent years have resulted in prolongation of life. Among our
growing elderly population, aortic stenosis (AS) is becoming
an important and increasingly prevalent condition. It is well
known to have a poor prognosis once it is symptomatic and
moreover is associated with significant morbidity, multiple and
prolonged hospital admissions and a significant reduction in
the quality of life.
The prevalence of calcific, degenerative AS increases with
advancing age and affects ~40% of people aged over 80 years
[1]. Once AS becomes symptomatic, life expectancy decre-
ases dramatically (Fig. 1). Until recently, the only definitive
treatment for severe AS has been surgical aortic valve repla-
cement (AVR).
In the general population, the risk of conventional aortic
valve surgery is low (about 3%) and even when valve replace-
ment is associated with concurrent coronary artery by-pass
grafting, the operative risk does not exceed 5%. However,
the risk of aortic valve surgery is significantly higher in the
elderly, who are therefore often denied treatment [2]. It is the
combination of an unmet need with a desire to find lower
risk and less invasive approaches that has driven the develop-
ment of percutaneous valve therapy, which is now an extre-
mely fast-growing area of cardiology. Percutaneous and mi-
nimally invasive treatment of valvular heart disease presents
a very attractive option for this high risk group.
In this article, we discuss the percutaneous alternatives to open
valve surgery and review the currently available techniques.
BALLOON AORTIC VALVULOPLASTY
Percutaneous balloon aortic valvuloplasty (BAV) was first de-
scribed by Cribier et al. [3] a quarter of a century ago in 1986.
They reported its successful use in three elderly patients with
symptomatic severe AS, who were either unsuitable for AVR
or had refused it. After initial enthusiasm, use of the techni-
que tapered off, particularly when it became apparent that
there was no mortality benefit [4–6]. Despite this, BAV rema-
ined a successful method of increasing aortic valve area and
reducing the mean and peak aortic valve gradient. There also
appeared to be an increase in cardiac output and decrease in
left ventricular (LV) end-diastolic pressure. More importantly,
at 30 days, 70% of patients had improvement of symptoms,
but this was transient and re-stenosis was frequent (~50% of
patients within 3–6 months). Moreover, the procedure itself
was considered high risk and cumbersome and therefore dec-
lined in popularity in the early 1990s.
In recent years, BAV has experienced something of a re-
naissance, largely due to the growth and development of trans-
Figure 1. Natural history of symptomatic aortic stenosis without
treatment. Survival curves show the interval from the onset of
symptoms to the time of death (approximately two years in
patient with heart failure, three years for those with syncope,
and five years for those with angina)
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catheter aortic valve therapy. The BAV technique has been
refined by modern balloons, guidewires, vascular closure de-
vices and improved imaging techniques. The introduction of
rapid pacing during the procedure has made balloon infla-
tion both more predictable and more effective, and has trans-
formed the ease with which the aortic valve can be dilated.
The transcatheter aortic valve implantation (TAVI) experien-
ce has taught us that this is a simple and safe thing to do,
even in the conscious/sedated patient.
The BAV is finding a well-defined role in the treatment
of patients with critical AS. Accepted indications for BAV are
now:
— bridge to definitive treatment (either open AVR or TAVI);
— bridge to new technology e.g. those patients whose aor-
tic annulus is too large for the currently available TAVI
devices;
— prior to pre-TAVI percutaneous coronary intervention
(PCI) which can often be complex and high risk in the
setting of severe AS;
— therapeutic trial — particularly in breathless patients with
the combination of severe AS, significant coronary artery
disease (CAD) and severe airways disease;
— palliative — while this is more controversial, some feel
that offering 3–6 months of symptomatic benefit to very
elderly patients is ethical and worthwhile.
The procedure is usually performed retrogradely via the
femoral artery. The aortic valve is crossed with an AL-1/2 ca-
theter and straight wire. An extra-stiff guidewire is positioned
toward the apex of the LV to allow support for balloon passa-
ge across the stenosed valve. The balloons are available in
different sizes, lengths and shapes; some of them have a ‘dog-
-bone’ shape to ensure a steady position during inflation.
More contemporary series of BAV [7] demonstrate that
while long-term survival is still low, procedural complications
(in particular vascular) have improved, as has procedural
mortality [8, 9]. Large arterial sheaths (9–14 F) are still neces-
sary and procedural complications therefore include bleeding
and vascular injury (10–20%). However, the incidence of other
complications is low and, rather surprisingly, severe valvular
regurgitation is uncommon (~1%).
TRANSCATHETER AORTIC
VALVE IMPLANTATION
Until recently, the only definitive treatment for AS was open
heart surgical AVR, which remains the gold standard.
However, the novel technique of percutaneous TAVI has
become feasible in recent years. Cribier et al. [10] performed
the first antegrade percutaneous aortic valve implantation in
2002, with the valve prosthesis advanced from the venous
circulation across the inter-atrial septum. This technique pro-
ved very technically demanding and difficult to reproduce,
prompting the development of two new approaches: retro-
grade/transfemoral/subclavian approach (Edwards Sapien va-
lve, CoreValve) or the anterograde/transapical (Edwards Sa-
pien valve) approach.
The two devices available for TAVI are currently the
Edwards Sapien bioprosthesis (Edwards Lifesciences, Inc.,
CA, USA) and the CoreValve ReValving system (Medtronic
CV, Luxembourg) (Fig. 2). The second generation of the
Edwards Sapien (Sapien XT) valve consists of three bovine
pericardial leaflets mounted within a balloon expandable,
cobalt chromium stent and are currently available in two
sizes (23 and 26 mm; 20 and 29 mm are in development).
The size of the fourth generation transfemoral delivery sys-
tem (NovaFlex™), which received its CE mark in March 2010,
has been reduced (22 F to 18 F and 24 F to 19 F). The
Edwards Sapien THV is deployed transapically using the
‘Ascendra 2™’ catheter. The most recent iteration of this
system enhances procedural control and sheath size has
been reduced from 26 F to 22 F (Fig. 3). The second gene-
ration of 20 mm and 29 mm valves are currently being te-
sted in clinical trials (PREVAIL). The CoreValve device has
three porcine pericardial leaflets within a larger, self-expan-
ding nitinol frame and is available in 26 mm and 29 mm
Figure 2. Edwards Sapien XT valve (A) and CoreValve prosthesis (B) before loading into the delivery system (CoreValve picture from
Grube et al. J Am Coll Cardiol, 2007)
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Figure 3. Edwards Sapien valve is deployed using a transfemoral or a transapical approach (picture from Edwards LifeSciences)
sizes delivered via an 18 F sheath. A summary of currently
available transfemoral systems is presented in Table 1.
Retrograde/transfemoral approach
After arterial puncture or surgical exposure of the artery, the
vessel is pre-dilated with a series of dilators of increasing size
to accommodate the appropriate size of delivery sheath.
Depending on the valve size, 18 F or 19 F introducer sheaths
are required for implantation of the Edwards Sapien XT valve
and 18 F for the CoreValve. As with balloon valvuloplasty,
valve implantation with the balloon-mounted Edwards Sa-
pien is achieved using rapid pacing to facilitate accurate de-
ployment of the prosthesis. The Edwards XT valve is crimped
proximal to the balloon and is moved onto the balloon in the
descending aorta. No rapid pacing is required during deploy-
ment of the CoreValve system. Haemostasis is usually achie-
ved by surgical repair or suture-mediated closure devices. With
currently available delivery systems, the TAVI procedure be-
comes a purely percutaneous procedure and in many cen-




Only the Edwards Sapien valve is currently available for use
via the transapical route. Access to the LV apex is gained thro-
ugh a left anterolateral minithoracotomy, with opening of the
pericardium. Under fluoroscopic guidance, the apex is punc-
tured and the valve is crossed anterogradely. After BAV, the
22 F Ascendra 2 delivery system is placed in the ventricle and
Table 1. Comparison of different CE marked transfemoral devices
Valve Stent Valve Frame Annulus Delivery Minimal
size height size sheath vessel diameter
Edwards Sapien XT 23 mm Cobalt chromium, Bovine 14.3 mm 18–22 mm 18 F > 6 mm
balloon expandable pericardium
26 mm Cobalt chromium, Bovine 17.2 mm 21–25 mm 19 F > 6.5 mm
balloon expandable pericardium
CoreValve 26 mm Nitinol self Porcine 50 mm 20–23 mm 18 F > 6 mm
expandable pericardium
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the valve is implanted using a similar technique to the trans-
femoral approach. The transapical sheath is removed and the
apex closed with purse-string sutures [11]. In addition, the
Edwards valve can be deployed utilising a transaortic appro-
ach via a mini sternotomy.
For patients unsuitable for the transfemoral approach,
the CoreValve device can be deployed via the subclavian
artery. This procedure is usually performed under general
anaesthesia but can be performed under regional/local ana-
esthesia.
INDICATIONS FOR TAVI
The TAVI is currently indicated in patients with severe symp-
tomatic calcific AS who are deemed too high risk for conven-
tional, surgical AVR. This diagnosis should obviously be deli-
neated by standard transthoracic echocardiography and oc-
casionally dobutamine stress echocardiography (in cases of
low gradient, low output AS) or/and transoesophageal echo-
cardiography. The TAVI is approved for use in patients with
a calculated risk of conventional surgery of > 20% (by Euro-
SCORE), > 10% (by STS) or those patients turned down for
conventional surgery by two cardiothoracic surgeons [12].
However, no scoring system currently exists which is specific
to TAVI and the EuroSCORE has significant limitations. Bro-
adly speaking, our own experience and the SOURCE registry
suggest that the EuroSCORE is a crude indication of TAVI out-
come, but does help to identify patients who may not benefit
from TAVI.
PATIENT SELECTION
The key to successful implementation of this new technique
is case selection and this is achieved via teamwork and a multi-
disciplinary approach. The team should consist of two inter-
ventional cardiologists, two cardiothoracic surgeons, an ima-
ging/echo specialist and a cardiac anaesthetist. Involvement
of other specialists (vascular surgeons, vascular radiologists,
physicians specialising in care of the elderly) is also necessa-
ry. Cases should be discussed and decisions made at a formal
multidisciplinary meeting.
The TAVI work-up investigations are shown in Table 2
and include a coronary (and ileofemoral) angiogram, right
heart catheterisation, computed tomography (CT) of aorta
and iliac arteries (often with 3D reconstruction), lung function
tests and duplex ultrasound of the carotid arteries. Co-exi-
sting CAD is not a contraindication for TAVI and PCI can be
performed pre-valve implantation in a patient with severe pro-
ximal coronary stenosis. The consensus is that concurrent co-
ronary disease should only be treated if the amount of myo-
cardium that is potentially ischaemic is large and likely to cause
significant problems during the TAVI procedure.
One of the most important components of the work-up
is the assessment of valve morphology and the sizing of the
aortic annulus. Correct valve sizing is critical to minimise the
potential for paravalvular regurgitation and to avoid prosthe-
sis migration. 3D TOE and CT are ideal in this regard, as the
aortic annulus is an oval structure and 3D techniques allow
measurements in multiple planes. The assessment of valve
morphology is vital as it helps to predict the severity and loca-
lisation of periprosthetic regurgitation or the risk of coronary
artery obstruction. The decision about valve size depends not
only on annulus size, but also on the severity of valve calcifi-
cation, the size of the LV outflow tract (LVOT), and the size of
the aortic root/sinuses.
As the commonest and most serious complications of
the transfemoral route are vascular, special attention should
be paid to the evaluation of size, tortuosity and calcification
of peripheral vessels to assess suitability for the transfemoral
approach. Angiography of the femoral and iliac arteries is the
gold standard to measure vessel diameter, but CT is also help-
ful in estimating calcification and tortuosity, particularly with
additional 3D reconstruction. The contraindications for trans-
femoral access include small calibre vessels (< 6 mm, de-
pending on the device used), severe tortuosity/calcification
of the iliac arteries, and severe intraluminal aortic atheroma.
In general terms, tortuosity is much more difficult to negotia-
te with any device in conjunction with calcification.
Clinical outcome
Early experience of TAVI was analysed in the Registry of En-
dovascular Critical Aortic Stenosis Treatment (RECAST) trial
from Cribier’s group [13]. Anatomical and procedural suc-
cess using the transfemoral technique exceeded 90% with
a low 30-day mortality (less than 10%). John Webb’s group
[14] initially reported a valve implantation success rate of 86%
with a 30-day mortality of about 12%. These initial results
Table 2. Pre-operative investigations necessary during patient






Transthoracic study (with annulus measurement)
Transoesophageal study (if annulus borderline
or if any doubt regarding anatomy)
Computed tomography scan of aorta:
3D reconstruction if available
Precise localisation of vessel wall calcium —





491Contemporary trans-catheter treatment of severe aortic stenosis
were influenced by a marked learning curve; procedural suc-
cess increased to 96% when experience had been gained.
The first CoreValve prosthesis was implanted in a human
in 2004. Again, the CoreValve was implanted in high-risk el-
derly patients with a procedural success rate of 92% and an
initial 30-day mortality of 15% [15].
Placement of AoRTic traNscathetER valves (PARTNER) is
the first randomised controlled trial to compare standard sur-
gical AVR to TAVI using the Edwards Sapien valve. At one
year, the rate of death from any cause was 30.7% with TAVI,
compared to 50.7% with standard therapy (p < 0.001). In
addition, among survivors at one year, the rate of cardiac symp-
toms (New York Heart Association [NYHA] class III or IV) was
lower among patients who had undergone TAVI than among
those who had received standard therapy [16].
The largest series of transapical procedures has been per-
formed by Walther et al. [17], who reported a similar success
rate to the transfemoral procedure (exceeding 90%) with a very
small risk of needing urgent femoro-femoral cardiopulmona-
ry bypass. The mortality rate is slightly higher using the trans-
apical approach, probably because trans-apical TAVI patients
have a significantly higher risk due to peripheral vascular di-
sease and renal failure, which are markers for a high athero-
ma burden and a poor outcome.
Access site complications were the commonest serious
complications, but smaller delivery systems are likely to re-
duce this. The risk of stroke is relatively low and varies from
2–6%. Atrioventricular block occurs relatively rarely after
Edwards Sapien valve implantation, but is more frequent with
self-expanding devices (e.g. CoreValve) with a need for pace-
maker implantation in up to 20% of cases [18].
Severe aortic regurgitation after valve implantation is very
rare, although mild to moderate para-valvular regurgitation with
no haemodynamic consequence is frequently observed (93.8%
in the SOURCE registry). Thirty-day mortality was 6.3% in trans-
femoral patients and 10.3% in transapical patients [19]. In our
own series published recently, procedural success was achie-
ved in 98%. Postoperative complications included stroke (6%),
complete atrioventricular block (5.3%), renal failure requiring
haemofiltration (9.3%), and vascular injury (8.6%). Overall
30-day mortality was 9.9% (n = 15), 6% for transfemoral ap-
proach and 13.1% for transapical approach (Table 3) [20].
COMPLICATIONS AND THEIR MANAGEMENT
A variety of complications can occur during the TAVI proce-
dure (Table 4) which can have important haemodynamic
consequences. We have found real-time 3D TOE invaluable
for the rapid identification of these problems, which can often
be quickly rectified. Such phenomena include:
— coronary air embolus — manifests as a wall motion ab-
normality;
— acute increase in mitral regurgitation – can be caused by
passage of the guidewire through the mitral subvalvular
apparatus, usually clearly seen with 3D TOE;
Table 3. Thirty-day mortality and clinical outcome
Edwards Sapien valve CoreValve
SOURCE TAVI UK Registry Kings Health Partners European Registry TAVI UK Registry
n = 1,038 [19] n = 402 [21] n = 151 [20] n = 1,243 [22] n = 460 [21]
30-day mortality 6.2% 8.9% 9.9% 6.7% 5.5%
TF 6.3% NA 6% NA NA
TA/subclavian approach 10.3% NA 13.1% 9.4% NA
Stroke 2.5% NA 6% 1.7% NA
Pacemaker 7% 7% 5.3% 12% 26%
Major vascular complications 7% 2.5% 8.6% 1.9% 4%
TF — transfemoral; TA — transapical
Table 4. Peri-procedural complications of TAVI apparent










Aortic regurgitation (paravalvular or intravalvular)
Atrioventricular block
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— severe aortic regurgitation — either after BAV or valve
deployment. Echo will quickly identify whether this is
intra- or para-prosthetic;
— cardiac/aortic rupture with haemopericardium.
Vascular complications should be identified and treated
promptly. It is mandatory to perform an iliac-femorogram at
the end of the procedure. Flow-limiting dissections of the iliac
arteries should be stented and ruptures of the iliacs or aorta
treated with covered stents if possible. Vascular radiologists/
/surgeons should be closely involved with any TAVI program-
me for this reason.
Based on preclinical tests, the anticipated durability of
the Edwards Sapien and the CoreValve should be similar to
currently available bioprosthetic valves. So far, there has been
no structural deterioration observed on routine follow-up
documented beyond seven years with the Cribier-Edwards
valve, and beyond five years with the CoreValve device. How-
ever, long-term follow-up data is needed from larger groups
of patients.
SUMMARY
Percutaneous treatment of valvular heart disease is now a re-
ality. The successful implementation of these interventions
depends on appropriate case selection, itself achieved via
excellent imaging techniques and a multidisciplinary appro-
ach. Rapidly advancing technology is making the procedures
safer, but awareness of potential complications and their ra-
pid identification is vital. This new field of transcatheter treat-
ment will involve even closer working between cardiologists
and cardiothoracic surgeons and is likely to increase, rather
than decrease, cardiothoracic workload.
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